TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33471291

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic treatments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integrated approaches (SBRT + systemic treatments)
Number of subjects: 0
Study: 33471594

Group type: EXPERIMENTAL
Intervention: Home environment in infancy
Number of subjects: 0
Study: 33471827

Group type: EXPERIMENTAL
Intervention: PDDM model intervention
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: PDDM model training for clinicians
Number of subjects: 61
Study: 33471949

Group type: EXPERIMENTAL
Intervention: docetaxel cisplatin 5-fluorouracil induction chemotherapy
Number of subjects: 0
Study: 33472397

Group type: EXPERIMENTAL
Intervention: Real-time cardiac magnetic resonance (RT-CMR) exercise imaging
Number of subjects: 75

Group type: COMPARATOR
Intervention: Right heart catheterization
Number of subjects: 75
Study: 33472409

Group type: EXPERIMENTAL
Intervention: Closed-loop system for managing type 1 diabetes
Number of subjects: 39
Study: 33472513

Group type: EXPERIMENTAL
Intervention: PTSD and insomnia group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 0
Study: 33472545

Group type: EXPERIMENTAL
Intervention: Intensively monitored antiretroviral pause (IMAP)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Baseline questionnaire before or after initiating IMAP
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Open-ended responses
Number of subjects: 32
Study: 33472575

Group type: EXPERIMENTAL
Intervention: Comprehensive stroke center patients
Number of subjects: 4340

Group type: EXPERIMENTAL
Intervention: Primary stroke center patients
Number of subjects: 4340
Study: 33472606

Group type: EXPERIMENTAL
Intervention: In utero ZIKV exposure
Number of subjects: 235

Group type: COMPARATOR
Intervention: ZIKV unexposed toddlers
Number of subjects: 235
Study: 33472666

Group type: EXPERIMENTAL
Intervention: Axitinib 3 mg twice daily (MTD)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Axitinib 1 mg twice daily
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Axitinib 2 mg twice daily
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Axitinib 3 mg twice daily
Number of subjects: 9
Study: 33472674

Group type: EXPERIMENTAL
Intervention: Tai Chi mind-body intervention
Number of subjects: 24

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 24
Study: 33472687

Group type: EXPERIMENTAL
Intervention: PMBL®
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 33472776

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 600
Study: 33473101

Group type: EXPERIMENTAL
Intervention: Personalized neoantigen peptide-pulsed autologous dendritic cell vaccine
Number of subjects: 12
Study: 33474638

Group type: EXPERIMENTAL
Intervention: Energy-restricted treatment
Number of subjects: 86
Study: 33474858

Group type: EXPERIMENTAL
Intervention: Aspirin provocation
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Aspirin desensitization
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Drug provocation
Number of subjects: 92
Study: 33474967

Group type: EXPERIMENTAL
Intervention: Lenvatinib
Number of subjects: 0
Study: 33474976

Group type: EXPERIMENTAL
Intervention: Initial hs-cTnT measures below the limit of quantification (LOQ: 6 ng/L)
Number of subjects: 1462

Group type: EXPERIMENTAL
Intervention: Low-risk HEART score with initial hs-cTnT below the LOQ
Number of subjects: 1462

Group type: EXPERIMENTAL
Intervention: 0/1-h algorithm
Number of subjects: 1462

Group type: EXPERIMENTAL
Intervention: 0/1-h algorithm with low HEART score
Number of subjects: 1462

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 1462
Study: 33475022

Group type: EXPERIMENTAL
Intervention: Mathematical computer-based approach to study AD in real life
Number of subjects: 0
Study: 33475231

Group type: EXPERIMENTAL
Intervention: Bayesian dynamic borrowing using a mixture prior combining informative prior from adult data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tipping point analysis
Number of subjects: 0
Study: 33475512

Group type: EXPERIMENTAL
Intervention: e-DSI (electronic decision support intervention)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mobility patterns recorded using GPS tracker and travel diary
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: User-centered co-design process
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Triangulation and comparison of data from all phases
Number of subjects: 60
Study: 33475675

Group type: EXPERIMENTAL
Intervention: Delayed sampling of intraoperative parathormone testing (ioPTH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline ioPTH
Number of subjects: 0
Study: 33475793

Group type: EXPERIMENTAL
Intervention: Intrathecal administration of 50 mg of hyperbaric prilocaine
Number of subjects: 10
Study: 33476231

Group type: EXPERIMENTAL
Intervention: Small-group preventive intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 33476252

Group type: EXPERIMENTAL
Intervention: Chronic Obstructive Pulmonary Disease Knowledge Questionnaire
Number of subjects: 0
Study: 33476432

Group type: EXPERIMENTAL
Intervention: Voxelotor treatment, dosage and duration not available
Number of subjects: 0
Study: 33476434

Group type: EXPERIMENTAL
Intervention: Rituximab, bendamustine, mitoxantrone (R-BM) followed by rituximab consolidation
Number of subjects: 76
Study: 33476492

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1,200 mg every 3 weeks
Number of subjects: 0
Study: 33476575

Group type: EXPERIMENTAL
Intervention: IRF4 antisense oligonucleotides (ASOs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IRF4 ASOs
Number of subjects: 0
Study: 33476658

Group type: EXPERIMENTAL
Intervention: Four approaches to treat actinic keratosis
Number of subjects: 0
Study: 33477665

Group type: EXPERIMENTAL
Intervention: Behavior related to treatment of LUTS
Number of subjects: 0
Study: 33477964

Group type: EXPERIMENTAL
Intervention: Customized human milk fortification using a multi-nutrient fortifier and modular supplements of protein and fat.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard human milk fortification (historical cohorts).
Number of subjects: 0
Study: 33477979

Group type: EXPERIMENTAL
Intervention: Cemiplimab (monoclonal antibody targeting PD1), administered for ten cycles
Number of subjects: 1
Study: 33478466

Group type: EXPERIMENTAL
Intervention: Spirometry data and standardized questionnaires
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Quality of life assessments (generic and disease-specific)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Social determinants of health analysis
Number of subjects: 80
Study: 33478469

Group type: EXPERIMENTAL
Intervention: Bolstered standard of care and family economic empowerment intervention (incentivized youth financial savings account, financial literacy training, peer mentorship)
Number of subjects: 702

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 702
Study: 33478583

Group type: EXPERIMENTAL
Intervention: Intersectoral care management (ICM) delivered by specially trained nurses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative and quantitative evaluation methods
Number of subjects: 0
Study: 33478637

Group type: EXPERIMENTAL
Intervention: Unplanned PCI after TAVR
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Balloon-expandable bioprosthesis
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Self-expandable bioprosthesis
Number of subjects: 133
Study: 33478646

Group type: EXPERIMENTAL
Intervention: TriClip transcatheter tricuspid valve repair system
Number of subjects: 85
Study: 33478647

Group type: EXPERIMENTAL
Intervention: Transcatheter treatment of secondary tricuspid regurgitation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 33478715

Group type: EXPERIMENTAL
Intervention: His bundle pacing (HBP) with SelectSecure Model 3830 lead
Number of subjects: 69
Study: 33478795

Group type: EXPERIMENTAL
Intervention: Adapted Dietary Inflammatory Index (ADII) at diagnosis
Number of subjects: 1478

Group type: EXPERIMENTAL
Intervention: Adapted Dietary Inflammatory Index (ADII) six months after diagnosis
Number of subjects: 1478
Study: 33478921

Group type: EXPERIMENTAL
Intervention: Carfilzomib in combination with bendamustine and rituximab
Number of subjects: 10
Study: 33478934

Group type: EXPERIMENTAL
Intervention: Dyslipidemic children
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 200
Study: 33479501

Group type: EXPERIMENTAL
Intervention: NeoVax, a long-peptide vaccine targeting up to 20 personal neoantigens per patient
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: NeoVax
Number of subjects: 8
Study: 33479511

Group type: EXPERIMENTAL
Intervention: Functional connectivity during frustration blocks
Number of subjects: 69

Group type: COMPARATOR
Intervention: Functional connectivity during nonfrustration blocks
Number of subjects: 69
Study: 33479856

Group type: EXPERIMENTAL
Intervention: LY3295668 erbumine 25 mg BID
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: LY3295668 erbumine 50 mg BID
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: LY3295668 erbumine 75 mg BID
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: LY3295668 erbumine (all doses)
Number of subjects: 12
Study: 33480187

Group type: EXPERIMENTAL
Intervention: Fornix deep brain stimulation (fx-DBS)
Number of subjects: 39
Study: 33480607

Group type: EXPERIMENTAL
Intervention: Conservative physical therapy (10 sessions)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (healthy controls); N=20
Number of subjects: 63
Study: 33480608

Group type: EXPERIMENTAL
Intervention: Paracetamol (analgesic)
Number of subjects: 206
Study: 33480855

Group type: EXPERIMENTAL
Intervention: Priority for the First Nursing Visit Tool (PREVENT)
Number of subjects: 0
Study: 33480854

Group type: EXPERIMENTAL
Intervention: Digital Marshmallow Test (DMT) app self-report measures of impulsivity
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Digital Marshmallow Test (DMT) app mobile behavioral tasks (Balloon Analogue Risk Task, Go-No-Go task)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: DMT app assessing impulsivity in daily life
Number of subjects: 116
Study: 33480862

Group type: EXPERIMENTAL
Intervention: Risk-reducing salpingo-oophorectomy (RRSO) before 45 years of age
Number of subjects: 750

Group type: COMPARATOR
Intervention: Control group (women who did not undergo RRSO or underwent RRSO after 55 years of age)
Number of subjects: 750
Study: 33481011

Group type: EXPERIMENTAL
Intervention: Baseline A1c
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: Follow-up A1c
Number of subjects: 942
Study: 33481150

Group type: EXPERIMENTAL
Intervention: Coaching Boys into Men (CBIM) program
Number of subjects: 2493
Study: 33481332

Group type: EXPERIMENTAL
Intervention: Prescribed light exercise (30 minutes of daily light exercise)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Standard mTBI instructions (gradual return to exercise following symptom resolution)
Number of subjects: 367

Group type: EXPERIMENTAL
Intervention: Prescribed light exercise
Number of subjects: 367

Group type: COMPARATOR
Intervention: Standard mTBI instructions
Number of subjects: 367
Study: 33481403

Group type: EXPERIMENTAL
Intervention: Intraoperative methadone (0.1 mg/kg, maximum 5 mg) and postoperative every 12 hours for 3-5 doses
Number of subjects: 38
Study: 33481418

Group type: EXPERIMENTAL
Intervention: Sleep disturbances (including sleep duration, sleep timing, and sleep disordered breathing)
Number of subjects: 0
Study: 33481552

Group type: EXPERIMENTAL
Intervention: ITx alone
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: ITx plus bone marrow-derived hematopoietic stem cells
Number of subjects: 35

Group type: COMPARATOR
Intervention: Discontinuation of immunosuppressive therapy
Number of subjects: 35
Study: 33481553

Group type: EXPERIMENTAL
Intervention: Uterus transplantation (UTx)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Increased existing baseline immunosuppression
Number of subjects: 13

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Modified histopathological grading system
Number of subjects: 13
Study: 33481557

Group type: EXPERIMENTAL
Intervention: MR-guided focused ultrasound (MRgFUS) ablation of the globus pallidus internus
Number of subjects: 20
Study: 33481672

Group type: EXPERIMENTAL
Intervention: Prior oral contraceptive use
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no prior oral contraceptive use)
Number of subjects: 0
Study: 33481989

Group type: EXPERIMENTAL
Intervention: ABC CAT (Computerized Adaptive Test)
Number of subjects: 406
Study: 33481995

Group type: EXPERIMENTAL
Intervention: Shoulder tissue irritability rating system (STAR-Shoulder)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Patient-reported outcome (PRO) measures
Number of subjects: 101
Study: 33482005

Group type: EXPERIMENTAL
Intervention: Gait variability measured as GaitSD
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fear of Pain Questionnaire (FOPQ)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fear of Pain Questionnaire (FOPQ) - Avoidance scores
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Functional Disability Inventory
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 6-Minute Walk Test
Number of subjects: 16
Study: 33482628

Group type: EXPERIMENTAL
Intervention: Pivot smoking cessation program
Number of subjects: 319
Study: 33482774

Group type: EXPERIMENTAL
Intervention: PConnect parent program co-led by parent peer facilitator and Head Start staff facilitator, 10 sessions
Number of subjects: 10
Study: 33483182

Group type: EXPERIMENTAL
Intervention: Sarcopenia
Number of subjects: 140

Group type: COMPARATOR
Intervention: External validation cohort
Number of subjects: 140
Study: 33483352

Group type: EXPERIMENTAL
Intervention: Repeat atrial fibrillation catheter ablation (AFCA) in women
Number of subjects: 443

Group type: COMPARATOR
Intervention: Repeat atrial fibrillation catheter ablation (AFCA) in men
Number of subjects: 443
Study: 33483617

Group type: EXPERIMENTAL
Intervention: Pevonedistat plus azacitidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Azacitidine (control)
Number of subjects: 0
Study: 33483802

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine infusion (0.15 mg/kg/h titrated toward 0.6 mg/kg/h)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine infusion
Number of subjects: 23
Study: 33483920

Group type: EXPERIMENTAL
Intervention: Cardiac autonomic modulation (CAM) in overweight and physically active adults
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Cardiac autonomic modulation (CAM) in normal weight groups
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Recommended levels of physical activity
Number of subjects: 256
Study: 33484136

Group type: EXPERIMENTAL
Intervention: Maternal lutein and zeaxanthin intake during pregnancy (mean daily intake: 2.6 mg)
Number of subjects: 1580
Study: 33484559

Group type: EXPERIMENTAL
Intervention: Patients with postsurgical hypoparathyroidism
Number of subjects: 20

Group type: COMPARATOR
Intervention: Age- and sex-matched controls
Number of subjects: 20
Study: 33484567

Group type: EXPERIMENTAL
Intervention: Orbital fibroblasts from GO patients
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control fibroblasts
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: GO fibroblasts
Number of subjects: 12
Study: 33484598

Group type: EXPERIMENTAL
Intervention: Longitudinal strain analysis in stroke patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Longitudinal strain analysis in healthy controls
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Septal S', MAD, global longitudinal strain rate, dynamic volumetry-derived parameters
Number of subjects: 30
Study: 33484819

Group type: EXPERIMENTAL
Intervention: Hungry (pre-lunch)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Satiated (post-lunch)
Number of subjects: 15
Study: 33485079

Group type: EXPERIMENTAL
Intervention: Perioperative capecitabine, oxaliplatin and trastuzumab (XELOX-T)
Number of subjects: 36
Study: 33485301

Group type: EXPERIMENTAL
Intervention: EFV 400 mg combined with tenofovir (TDF) and lamivudine (3TC) for 48 weeks
Number of subjects: 20
Study: 33485345

Group type: EXPERIMENTAL
Intervention: Cementless titanium-coated, isoelastic monoblock cup with vitamin E-blended highly cross-linked polyethylene (HXLPE)
Number of subjects: 101
Study: 33485461

Group type: EXPERIMENTAL
Intervention: Surgery for gastric cancer in low-income or lower-middle-income countries
Number of subjects: 15958

Group type: EXPERIMENTAL
Intervention: Surgery for colorectal cancer in low-income or lower-middle-income countries
Number of subjects: 15958

Group type: EXPERIMENTAL
Intervention: Surgery for colorectal cancer in upper-middle-income countries
Number of subjects: 15958

Group type: EXPERIMENTAL
Intervention: Surgery with major complications in low-income or lower-middle-income countries
Number of subjects: 15958

Group type: EXPERIMENTAL
Intervention: Surgery with major complications in upper-middle-income countries
Number of subjects: 15958
Study: 33485708

Group type: EXPERIMENTAL
Intervention: Individualized food-based nutrition intervention program (6 months duration, caloric restriction of 500-1000 kcal/d when applicable, protein intake of 1.2-1.5 g/kgBW/d, 5-9 servings/day of fruits and vegetables)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Individualized food-based nutrition intervention program
Number of subjects: 22
Study: 33485799

Group type: EXPERIMENTAL
Intervention: Imiglucerase treatment
Number of subjects: 475
Study: 33486083

Group type: EXPERIMENTAL
Intervention: Lifestyle modifications for weight loss
Number of subjects: 0
Study: 33486223

Group type: EXPERIMENTAL
Intervention: Daily egg intake
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Higher consumption of eggs
Number of subjects: 48
Study: 33486874

Group type: EXPERIMENTAL
Intervention: IFN
Number of subjects: 420

Group type: COMPARATOR
Intervention: NUC-IFN
Number of subjects: 420
Study: 33486971

Group type: EXPERIMENTAL
Intervention: Noninvasive ultrasound therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33486983

Group type: EXPERIMENTAL
Intervention: Postural tachycardia syndrome (PoTS)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 19
Study: 33487029

Group type: EXPERIMENTAL
Intervention: Second-line antiretroviral (ART) treatment
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (QoL) assessment at week 4
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Adjustment for self-reported adherence at week 4, VL and CD4 at baseline, cognitive functioning, pain and mental health domains
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Post-hoc analysis of QoL and adherence
Number of subjects: 500
Study: 33487127

Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxyvitamin D (1,25(OH)D); specific dosage and duration not mentioned
Number of subjects: 0
Study: 33487129

Group type: EXPERIMENTAL
Intervention: Modified Atkins Diet (MAD)
Number of subjects: 31
Study: 33487279

Group type: EXPERIMENTAL
Intervention: Triheptanoin treatment for 78 weeks
Number of subjects: 78
Study: 33487289

Group type: EXPERIMENTAL
Intervention: Qualitative-quantitative food plan for 6 months
Number of subjects: 6
Study: 33487299

Group type: EXPERIMENTAL
Intervention: Alternate day fasting (ADF) with a low carbohydrate diet (600 kcal 'fast day' alternated with an ad libitum 'feast day')
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Alternate day fasting (ADF) with a low carbohydrate diet
Number of subjects: 31
Study: 33487468

Group type: EXPERIMENTAL
Intervention: 1 μg CV7202
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 2 μg CV7202
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 5 μg CV7202
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 1 μg CV7202 (after two doses)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 2 μg CV7202 (after two doses)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Rabipur (Control)
Number of subjects: 55
Study: 33487525

Group type: EXPERIMENTAL
Intervention: Higher isometric muscle strength
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Distance reached in the 6MWT
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Higher AT stiffness
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Ankle power
Number of subjects: 22
Study: 33487824

Group type: EXPERIMENTAL
Intervention: Articaine 2% (40 ml)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Articaine 2% mixed with dexmedetomidine (1 μg.kg) (40 ml)
Number of subjects: 50
Study: 33488576

Group type: EXPERIMENTAL
Intervention: PCI with fimaporfin + light
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (Hiltonol and vaccine antigens only)
Number of subjects: 96
Study: 33489806

Group type: EXPERIMENTAL
Intervention: Treatment patterns (type/duration, number of lines, completion rate)
Number of subjects: 8800

Group type: EXPERIMENTAL
Intervention: Early-stage treatment (starting from 1 December 2010)
Number of subjects: 8800

Group type: EXPERIMENTAL
Intervention: Data collection at baseline (diagnosis) and 6 and 12 months after
Number of subjects: 8800

Group type: EXPERIMENTAL
Intervention: Kaplan-Meier curves for treatment duration and overall survival
Number of subjects: 8800

Group type: EXPERIMENTAL
Intervention: Cox-proportional hazards models
Number of subjects: 8800

Group type: EXPERIMENTAL
Intervention: Multivariate logistic regression
Number of subjects: 8800
Study: 33490196

Group type: COMPARATOR
Intervention: SOX (S-1 plus oxaliplatin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SOXA (S-1 plus oxaliplatin combined with apatinib)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SOXAP (S-1 plus oxaliplatin combined with apatinib and camrelizumab)
Number of subjects: 0
Study: 33490296

Group type: EXPERIMENTAL
Intervention: UCB-MSC-HA implantation
Number of subjects: 114

Group type: COMPARATOR
Intervention: Microfracture
Number of subjects: 114
Study: 33490640

Group type: EXPERIMENTAL
Intervention: Mobile outreach team approach with oral anti-TB treatment under DOTS
Number of subjects: 200

Group type: COMPARATOR
Intervention: Facility-based DOTS treatment according to WHO recommendations
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Mobile outreach team approach
Number of subjects: 200
Study: 33490707

Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiotherapy (SABR) - 20Gy single fraction followed by pembrolizumab - 200 mg every 3 weeks for 8 cycles
Number of subjects: 30